Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 4Dermatologic 4Breast 3Head & Neck 2Genitourinary 2Thoracic 1Plasma cell 1Lymphoid 1Gynecologic 1Gastrointestinal 1

Conditions

Prostatic Neoplasms 5Urinary Bladder Neoplasms 4Melanoma 4Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 3Sarcoma 2Ovarian Neoplasms 2Esophageal Neoplasms 2Carcinoma, Merkel Cell 2Uterine Cervical Neoplasms 1Urologic Neoplasms 1Testicular Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Neoplasms, Squamous Cell 1Neoplasms, Plasma Cell 1Metastatic Castration-resistant Prostate Cancer 1Lymphoma, T-Cell, Cutaneous 1Lung Neoplasms 1Kidney Neoplasms 1Chondrosarcoma 1Carcinoma, Transitional Cell 1Carcinoma, Hepatocellular 1Adenocarcinoma 1

Interventions

Filgrastim 13Carboplatin 10Cyclophosphamide 9pembrolizumab 8Radiosurgery 8Ifosfamide 8Magnetic Resonance Spectroscopy 7Etoposide 7Biopsy 7Specimen Handling 6Doxorubicin 6X-Rays 5Phantoms, Imaging 5Peripheral Blood Stem Cell Transplantation 5Paclitaxel 5Granulocyte Colony-Stimulating Factor 5Gemcitabine 5Cisplatin 5pazopanib 4palbociclib 4Thiotepa 4Temozolomide 4Radiotherapy 4Nuclear Medicine Department, Hospital 4Nivolumab 4Mesna 4Melphalan 4Docetaxel 4Busulfan 4Blood Specimen Collection 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Sarcoma × poly ICLC × Genitourinary × Clear all
NCT02643303 2022-12-02

A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers

Ludwig Institute for Cancer Research

Phase 1/2 Completed
58 enrolled 24 charts
BreastDermatologicGenitourinaryHead & NeckLymphoidSarcoma

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Kidney Neoplasms, Melanoma, Prostatic Neoplasms, Sarcoma, Testicular Neoplasms, Carcinoma, Merkel Cell, Lymphoma, T-Cell, Cutaneous

NCT00948961 2016-06-27

A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1

Celldex Therapeutics

Phase 1/2 Completed
70 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicPlasma cellSarcomaThoracic

Adenocarcinoma, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Chondrosarcoma, Esophageal Neoplasms, Melanoma, Ovarian Neoplasms, Sarcoma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡